Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors

Detalhes bibliográficos
Autor(a) principal: Santos,Lucianna Helene
Data de Publicação: 2015
Outros Autores: Ferreira,Rafaela Salgado, Caffarena,Ernesto Raúl
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Memórias do Instituto Oswaldo Cruz
Texto Completo: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762015000700847
Resumo: Reverse transcriptase (RT) is a multifunctional enzyme in the human immunodeficiency virus (HIV)-1 life cycle and represents a primary target for drug discovery efforts against HIV-1 infection. Two classes of RT inhibitors, the nucleoside RT inhibitors (NRTIs) and the nonnucleoside transcriptase inhibitors are prominently used in the highly active antiretroviral therapy in combination with other anti-HIV drugs. However, the rapid emergence of drug-resistant viral strains has limited the successful rate of the anti-HIV agents. Computational methods are a significant part of the drug design process and indispensable to study drug resistance. In this review, recent advances in computer-aided drug design for the rational design of new compounds against HIV-1 RT using methods such as molecular docking, molecular dynamics, free energy calculations, quantitative structure-activity relationships, pharmacophore modelling and absorption, distribution, metabolism, excretion and toxicity prediction are discussed. Successful applications of these methodologies are also highlighted.
id FIOCRUZ-4_00514c6e5ab7f5ee9a78f8825c0e92fb
oai_identifier_str oai:scielo:S0074-02762015000700847
network_acronym_str FIOCRUZ-4
network_name_str Memórias do Instituto Oswaldo Cruz
spelling Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitorsHIV-1computer-aided drug designreverse transcriptase inhibitorsmolecular modellingReverse transcriptase (RT) is a multifunctional enzyme in the human immunodeficiency virus (HIV)-1 life cycle and represents a primary target for drug discovery efforts against HIV-1 infection. Two classes of RT inhibitors, the nucleoside RT inhibitors (NRTIs) and the nonnucleoside transcriptase inhibitors are prominently used in the highly active antiretroviral therapy in combination with other anti-HIV drugs. However, the rapid emergence of drug-resistant viral strains has limited the successful rate of the anti-HIV agents. Computational methods are a significant part of the drug design process and indispensable to study drug resistance. In this review, recent advances in computer-aided drug design for the rational design of new compounds against HIV-1 RT using methods such as molecular docking, molecular dynamics, free energy calculations, quantitative structure-activity relationships, pharmacophore modelling and absorption, distribution, metabolism, excretion and toxicity prediction are discussed. Successful applications of these methodologies are also highlighted.Instituto Oswaldo Cruz, Ministério da Saúde2015-11-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762015000700847Memórias do Instituto Oswaldo Cruz v.110 n.7 2015reponame:Memórias do Instituto Oswaldo Cruzinstname:Fundação Oswaldo Cruzinstacron:FIOCRUZ10.1590/0074-02760150239info:eu-repo/semantics/openAccessSantos,Lucianna HeleneFerreira,Rafaela SalgadoCaffarena,Ernesto Raúleng2020-04-25T17:52:10Zhttp://www.scielo.br/oai/scielo-oai.php0074-02761678-8060opendoar:null2020-04-26 02:20:33.622Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruztrue
dc.title.none.fl_str_mv Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors
title Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors
spellingShingle Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors
Santos,Lucianna Helene
HIV-1
computer-aided drug design
reverse transcriptase inhibitors
molecular modelling
title_short Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors
title_full Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors
title_fullStr Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors
title_full_unstemmed Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors
title_sort Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors
author Santos,Lucianna Helene
author_facet Santos,Lucianna Helene
Ferreira,Rafaela Salgado
Caffarena,Ernesto Raúl
author_role author
author2 Ferreira,Rafaela Salgado
Caffarena,Ernesto Raúl
author2_role author
author
dc.contributor.author.fl_str_mv Santos,Lucianna Helene
Ferreira,Rafaela Salgado
Caffarena,Ernesto Raúl
dc.subject.por.fl_str_mv HIV-1
computer-aided drug design
reverse transcriptase inhibitors
molecular modelling
topic HIV-1
computer-aided drug design
reverse transcriptase inhibitors
molecular modelling
dc.description.none.fl_txt_mv Reverse transcriptase (RT) is a multifunctional enzyme in the human immunodeficiency virus (HIV)-1 life cycle and represents a primary target for drug discovery efforts against HIV-1 infection. Two classes of RT inhibitors, the nucleoside RT inhibitors (NRTIs) and the nonnucleoside transcriptase inhibitors are prominently used in the highly active antiretroviral therapy in combination with other anti-HIV drugs. However, the rapid emergence of drug-resistant viral strains has limited the successful rate of the anti-HIV agents. Computational methods are a significant part of the drug design process and indispensable to study drug resistance. In this review, recent advances in computer-aided drug design for the rational design of new compounds against HIV-1 RT using methods such as molecular docking, molecular dynamics, free energy calculations, quantitative structure-activity relationships, pharmacophore modelling and absorption, distribution, metabolism, excretion and toxicity prediction are discussed. Successful applications of these methodologies are also highlighted.
description Reverse transcriptase (RT) is a multifunctional enzyme in the human immunodeficiency virus (HIV)-1 life cycle and represents a primary target for drug discovery efforts against HIV-1 infection. Two classes of RT inhibitors, the nucleoside RT inhibitors (NRTIs) and the nonnucleoside transcriptase inhibitors are prominently used in the highly active antiretroviral therapy in combination with other anti-HIV drugs. However, the rapid emergence of drug-resistant viral strains has limited the successful rate of the anti-HIV agents. Computational methods are a significant part of the drug design process and indispensable to study drug resistance. In this review, recent advances in computer-aided drug design for the rational design of new compounds against HIV-1 RT using methods such as molecular docking, molecular dynamics, free energy calculations, quantitative structure-activity relationships, pharmacophore modelling and absorption, distribution, metabolism, excretion and toxicity prediction are discussed. Successful applications of these methodologies are also highlighted.
publishDate 2015
dc.date.none.fl_str_mv 2015-11-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762015000700847
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762015000700847
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/0074-02760150239
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto Oswaldo Cruz, Ministério da Saúde
publisher.none.fl_str_mv Instituto Oswaldo Cruz, Ministério da Saúde
dc.source.none.fl_str_mv Memórias do Instituto Oswaldo Cruz v.110 n.7 2015
reponame:Memórias do Instituto Oswaldo Cruz
instname:Fundação Oswaldo Cruz
instacron:FIOCRUZ
reponame_str Memórias do Instituto Oswaldo Cruz
collection Memórias do Instituto Oswaldo Cruz
instname_str Fundação Oswaldo Cruz
instacron_str FIOCRUZ
institution FIOCRUZ
repository.name.fl_str_mv Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruz
repository.mail.fl_str_mv
_version_ 1669937719206215680